These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 19129019)

  • 1. Investigating the interaction between oncogene and tumor suppressor protein.
    Pirogova E; Akay M; Cosic I
    IEEE Trans Inf Technol Biomed; 2009 Jan; 13(1):10-5. PubMed ID: 19129019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of bioactive and structurally well-defined peptides from conformationally restricted libraries.
    Pastor MT; Mora P; Ferrer-Montiel A; Pérez-Payá E
    Biopolymers; 2004; 76(4):357-65. PubMed ID: 15386263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a function-specific mutation of clathrin heavy chain (CHC) required for p53 transactivation.
    Ohata H; Ota N; Shirouzu M; Yokoyama S; Yokota J; Taya Y; Enari M
    J Mol Biol; 2009 Dec; 394(3):460-71. PubMed ID: 19766654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades.
    Bidwell GL; Raucher D
    Expert Opin Drug Deliv; 2009 Oct; 6(10):1033-47. PubMed ID: 19637980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation.
    Ishimaru D; Ano Bom AP; Lima LM; Quesado PA; Oyama MF; de Moura Gallo CV; Cordeiro Y; Silva JL
    Biochemistry; 2009 Jul; 48(26):6126-35. PubMed ID: 19505151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the interaction between the N-terminal domain of the tumor suppressor p53 and azurin.
    Taranta M; Bizzarri AR; Cannistraro S
    J Mol Recognit; 2009; 22(3):215-22. PubMed ID: 19140135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interaction of oncogene and anti-oncogene products].
    Zang J; Zhou AR
    Sheng Li Ke Xue Jin Zhan; 1991 Jan; 22(1):34-7. PubMed ID: 1829543
    [No Abstract]   [Full Text] [Related]  

  • 8. Macromolecular bioactivity: is it resonant interaction between macromolecules?--Theory and applications.
    Cosic I
    IEEE Trans Biomed Eng; 1994 Dec; 41(12):1101-14. PubMed ID: 7851912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domain Interaction Footprint: a multi-classification approach to predict domain-peptide interactions.
    Schillinger C; Boisguerin P; Krause G
    Bioinformatics; 2009 Jul; 25(13):1632-9. PubMed ID: 19376827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
    Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
    Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: a comparative study.
    Almansour NM; Pirogova E; Coloe PJ; Cosic I; Istivan TS
    Future Med Chem; 2012 Aug; 4(12):1553-65. PubMed ID: 22917245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding mutations and protein stability through tripeptides.
    Anishetty S; Anishetty R; Pennathur G
    FEBS Lett; 2006 Apr; 580(8):2071-80. PubMed ID: 16546179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular perspective: p53 tumor suppressor.
    Goodsell DS
    Stem Cells; 1999; 17(3):189-90. PubMed ID: 10342561
    [No Abstract]   [Full Text] [Related]  

  • 14. Electronic structure and physicochemical properties characterization of the amino acids 12-26 of TP53: a theoretical study.
    Barrientos-Salcedo C; Arenas-Aranda D; Salamanca-Gómez F; Ortiz-Muñiz R; Soriano-Correa C
    J Phys Chem A; 2007 May; 111(20):4362-9. PubMed ID: 17472350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights from a novel p53 isoform in zebrafish want to reel us in, but will we take the bait?
    Manfredi JJ
    Genes Dev; 2009 Feb; 23(3):261-4. PubMed ID: 19204113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.
    Rampias T; Sasaki C; Weinberger P; Psyrri A
    J Natl Cancer Inst; 2009 Mar; 101(6):412-23. PubMed ID: 19276448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling and mutational evidence identify the substrate binding site and functional elements in APC amino acid transporters.
    Vangelatos I; Vlachakis D; Sophianopoulou V; Diallinas G
    Mol Membr Biol; 2009 Aug; 26(5):356-70. PubMed ID: 19670073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttranslational modifications affect the interaction of S100 proteins with tumor suppressor p53.
    van Dieck J; Teufel DP; Jaulent AM; Fernandez-Fernandez MR; Rutherford TJ; Wyslouch-Cieszynska A; Fersht AR
    J Mol Biol; 2009 Dec; 394(5):922-30. PubMed ID: 19819244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Water, shape recognition, salt bridges, and cation-pi interactions differentiate peptide recognition of the HIV rev-responsive element.
    Michael LA; Chenault JA; Miller BR; Knolhoff AM; Nagan MC
    J Mol Biol; 2009 Sep; 392(3):774-86. PubMed ID: 19631217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation.
    Montano X
    Oncogene; 2009 Oct; 28(43):3787-800. PubMed ID: 19749791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.